Ligand’s Stock Rises After Bank of America Adds a Buy Rating

Bank of America has added Ligand Pharmaceuticals to its list of stocks it recommends buying, setting a new price target at $244. The move comes as the bank highlights Ligand’s business model, which focuses on high‑margin products and a lower level of risk compared to many other biopharma companies.

Recommendation issued: March 11, 2026
Pre‑market reaction: Stock climbed

Why BofA Loves Ligand

• Specialty drugs with strong pricing power – A strategy that can generate steady cash flow even in a competitive market.
• High‑margin therapies – The pipeline targets niche patient groups, reducing exposure to broader market swings while maintaining profitability.
• Lower risk profile – Compared to many biopharma peers, Ligand’s focus on specialty products offers a more stable growth outlook.

Market Context

Ligand has experienced years of volatility, facing challenges with drug approvals and market competition. The new rating suggests that investors may view Ligand’s recent developments as a turning point, offering a more stable growth outlook.

Investor Takeaway

The bank’s endorsement may encourage investors—especially those seeking solid earnings prospects and manageable risk profiles—to add Ligand to their portfolios. The recommendation reflects a belief that Ligand’s current strategy is positioned to deliver consistent returns, making it an attractive option for buyers seeking a blend of growth and stability.